Abstract
Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, is characterized by progressive damage to supportive layers and photoreceptor cell loss. No current therapy halts vision loss. Numerous genetic and/or environmental factors likely contribute to the initiating events leading to AMD. Progressive events from cellular dysfunction and tissue destruction result in the histopathological features of AMD including drusen formation, basal laminar deposits, accumulation of lipofuscin in the retinal pigmented epithelium (RPE), thickening of Bruch's membrane, choriovasculature and RPE cell loss, and photoreceptor cell death. Studies on the biochemical and physiological perturbations seen in the RPE, Bruch's membrane and the choroid correlate well with AMD, however, progressive events leading to these characteristic features are not well understood. Resolving these issues is essential for successful therapeutic intervention of AMD. We propose that receptor-mediated cellular activation by advanced glycation end (AGE) products, a major contributor to progressive tissue damage in other aging disorders, may also contribute significantly to progressive damage in AMD. In this paper, we review and compare pathological features of AMD to AGE/RAGE- mediated progressive events incurred in other aging disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alizadeh, M., Wada, M., Gelfman, C. M., Handa, J. T., and Hjelmeland, L. M., 2001, Downregulation of differentiation specific gene expression by oxidative stress in ARPE-19 cells. Invest Ophthalmol. Vis. SO. 42:2706.
Boulton, M.and Dayhaw-Barker, P., 2001, The role of the retinal pigment epithelium: topographical variation and ageing change, Eye 15:384.
Droge, W., 2002, Free radicals in the physiological control of cell function. Physiol. Rev. 82:47.
Farboud, B., Aotaki-Keen, A., Miyata, T., Hjelmeland, L. M., and Handa, J. T., 1999, Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Mol. Vis. 5:11.
Glomb, M. A. and Pfahler, C., 2001, Amides are novel protein modifications formed by physiological sugars. J. Biol. Chem. 276:41638.
Guidry, C., Medeiros, N. E., and Curcio, C. A., 2002, Phenotypic variation of retinal pigment epithelium in age-related macular degeneration. Invest Ophthalmol. Vis. Sci. 43:267.
Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., Neurath, M. F., Slattery, T., Beach, D., McClary, J., Nagashima, M., Morser, J., Stern, D., and Schmidt, A. M., 1999, RAGE mediates a novel proinflammatory axis: a central cell surface receptor for 5100/calgranulin polypeptides. Cell 97:889.
Honda, S., Farboud, B., Hjelmeland, L. M., and Handa, J. T., 2001, Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced glycation end products in vitro. Invest Ophthalmol. Vis. Sci. 42:2419.
Ishibashi, T., Murata, T., Hangai, M., Nagai, R., Horiuchi, S., Lopez, P. F., Hinton, D. R., and Ryan, S. J., 1998, 'Advanced glycation end products in age-related macular degeneration. Arch. Ophthalmol. 116:1629.
 Jenkins, A. J., Cooper, M. E., and Stitt, A. W., 2002, Advanced glycation end products and diabetic complications. Expert. Opin. Investig. Drugs 11:1205.
Kislinger, T., Fu, C., Huber, B., Qu, W., Taguchi, A., Du, Y.S., Hofmann, M., Yan, S. F., Pischetsrieder, M., Stern, D., and Schmidt, A. M., 1999, N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274:31740.
Mata, N. L., Tzekov, R. T., Liu, X., Weng ,J., Birch, D. G., and Travis, G. H., 2001, Delayed dark-adaptation and lipofuscin accumulation in abcr+/- mice: implications for involvement of ABCR in age-related macular degeneration. Invest Ophthalmol. Vis. Sci. 42:1685
Park, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J. Jr., Chow, W. S., Stem, D., and Schmidt, A. M., 1998, Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1025.
Rakoczy, P. E., Zhang, D., Robertson, T., Barnett, N. L., Papadimitriou, J., Constable, I. J., and Lai, C. M., 2002, Progressive age-related changes similar to age-related macular degeneration in a transgenic mouse model. Am. J. Pathol. 161:1515.
Sarks, J. P., Sarks, S. H., and Killingsworth, M.C., 1994, Evolution of soft drusen in age-related macular degeneration. Eye 8:269.
Singh, R., Barden, A., Mori, T., and Beilin, L., 2001, Advanced glycation end-products: a review. Diabetologia 44:129.
Schmidt, A. M., Yan, S. D., Wautier, J. L., and Stern, D., 1999, Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84: 489.
Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M., 2001, The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest 108:949.
Stern, D. M., Yan, S. D., Yan, S. F., and Schmidt, A. M., 2002, Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev. 1:1.
Stitt, A. W. 2001, Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J Ophthalmol. 85:746.
Sun, H. and Nathans, J., 2001, ABCR, the ATP-binding cassette transporter responsible for Stargardt macular dystrophy, is an efficient target of all-trans-retinal-mediated photooxidative damage in vitro. Implications for retinal disease. JBiol. Chem. 276:11766.
Thornalley, P. J. 1998, Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol. Biol. (Noisy. -le-grand) 44:1013.
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., and Van Obberghen, E., 2001, Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem. 276:43836.
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., and Cerami, A., 1994, Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A 91:4766.
Winkler, B. S., Boulton, M. E., Gottsch, J. D., and Sternberg, P., 1999, Oxidative damage and age-related macular degeneration. Mol. Vis. 5:32.
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A., M., 1996, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685.
Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., and Kindy, M., 2000, Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6:643.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this paper
Cite this paper
Howes, K.A., Frederick, J.M., Marks, A., Baehr, W. (2003). Progressive Pathways in Age-Related Macular Degeneration. In: LaVail, M.M., Hollyfield, J.G., Anderson, R.E. (eds) Retinal Degenerations. Advances in Experimental Medicine and Biology, vol 533. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0067-4_12
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0067-4_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4909-9
Online ISBN: 978-1-4615-0067-4
eBook Packages: Springer Book Archive